Sign inJoin waitlistJoin the waitlist

Ruta Arays

Assistant Professor · University of Kentucky College of Medicine

Credentials: · · · · · ·

History

University of Kentucky College of Medicine
Present

Hematology and Medical Oncology
2017–2020
Internal Medicine
OhioHealth
2014–2017
Univ of Toledo Coll of Med
2010–2014

Research

Common variable immunodeficiency, immune thrombocytopenia, rituximab and splenectomy: important considerations
Case report · Postgraduate Medicine · 2016 · First of 3 authors · 5 citations
The Effect of an Educational Pamphlet on Patient Knowledge of and Intention to Discuss Screening for Obstructive Sleep Apnea in the Acute Ischemic Stroke Population
Journal of Neuroscience Nursing · 2018 · 4 citations
Inpatient management strategies in a severe case of heparin-induced thrombocytopenia
Case report · Transfusion and Apheresis Science · 2019 · 2 citations

Aaron Shmookler
3 papers
KJ
Kim Jordan
2 papers
Joanna Kolodney
1 paper
Kenneth Veselicky
1 paper
Paul McCarthy
1 paper · 1 as a fellow
PW
Peng Wang
1 paper
Ryan Donald
1 paper · 1 as a fellow
SG
Sahil Goyal
1 paper · 1 as a resident
SM
Samuel Merrill
1 paper
SY
Stephen Yu
1 paper · 1 as a fellow
Thomas Hogan
1 paper
ZA
Zeeshan Ahmad
1 paper · 1 as a fellow

Clinical trials

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Principal investigator · Recruiting · Phase 1
Rina Plattner
2022–2030
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2029
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2024–2027
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033